ArticleLangenbeck's archives of surgery2025
Long-term outcomes of S-1 monotherapy in stage IIIA gastric cancer with small tumors and low nodal involvement.
Article in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Japan, adjuvant chemotherapy with docetaxel/S-1 is recommended for stage III gastric cancer. However, this regimen may not be suitable for all patients due to toxicity and tolerability issues, particularly in older individuals or those with comorbidities. This study aimed to explore prognostic factors in stage IIIA gastric cancer and assess long-term outcomes in patients treated with S-1 monotherapy after curative gastrectomy.
methodsWe retrospectively analyzed 73 patients with stage IIIA gastric cancer (UICC 7th edition) who underwent curative gastrectomy and received postoperative adjuvant S-1 monotherapy between 2005 and 2018.Various prognostic factors, including preoperative (age, sex, BMI, tumor markers), perioperative (surgical approach, operative duration, blood loss, complications), and tumor-related variables (tumor size, lymph node status, histological features), were analyzed. Recurrence-free survival (RFS) was the primary endpoint, and cut-off values were determined using ROC analysis. Cox proportional hazards models were used for univariate and multivariate analyses.
resultsThe 3- and 5-year RFS rates were 71.7% and 64.3%, respectively. Multivariate analysis identified smaller tumor size (≤ 55.0 mm, P = 0.006) and lower lymph node positivity rate (≤ 0.079, P = 0.008) as independent favorable prognostic factors.
conclusionS-1 monotherapy may be associated with favorable long-term outcomes in selected patients with stage IIIA gastric cancer who have small tumors and low lymph node positivity rates. While these results are encouraging, they should not be interpreted as a rationale for broadly recommending S-1 monotherapy. Further studies are needed to define its role in individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.